DUBLIN, Jan. 20, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/wbb8tn/human_microbiome) has announced the addition of the "Human Microbiome Market by Indication, Application, Product, Product Research & Technology Research - Global Forecast to 2023" report to their offering.
The human microbiome market is expected to reach USD 658 Million by 2023 from USD 294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023).
The market is driven by growing incidences of unhealthy lifestyle diseases, and increase in occurrence of autoimmune disorders. However, government regulation and lack of detailed research may restrain the growth of this market to an extent. Investing in probiotic and prebiotic products, medical foods, drugs, and devices will prove fruitful for companies in the future.
The applications segment is further subdivided into therapeutics and diagnostics. Therapeutics may be the leading segment, owing to growing population and diseases. Currently, the diagnostics segment has fewer products in the pipeline than the therapeutics segment.
The products segment is subdivided into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Growth in these segments will be majorly driven due to use of probiotics and prebiotics for maintaining gut flora to avoid lifestyle diseases.
The human microbiome research spending market, by product, is divided characterized into instruments and consumables. The instruments segment is further segmented into laboratory instruments and analyzers, while, the consumables segment is further bifurcated into kits and reagents. The consumables segment is estimated to be the fastest - growing segment by 2020, owing to the repeated purchases of consumables as compared to instruments.
The human microbiome research spending market, by technology, is divided into cell culture technology, high- throughput technology, omics technology, and computational tools. The cell culture technology is the most widely-used technology in microbiome research, and is expected to account for the largest share of the human microbiome research spending market in 2015. The large share of this segment can be attributed to its usage in the in vitro model to reproduce in vivo conditions and to study host-microbial community interactions.
The geographic analysis reveals that Europe will account for the largest share within the forecast period of 2019 to 2023, due to high acceptance of probiotic and prebiotic products. Asia is expected to be a profitable region for the human microbiome market and poised to grow at a healthy CAGR in the forecast period. North America will show a low market share; however, it is expected to grow at a high CAGR from 2019 to 2023.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
For more information visit
Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets